主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Dou Dou Li Yaru Wang Lu Feng Yi Jiang Luyang
单位:
英文单位:Department of Anesthesiology Peking University People′s Hospital Beijng 100044 China
关键词:瑞马唑仑;镇静药;苯二氮类
英文关键词:Remimazolam;Sedative;Benzodiazepine
瑞马唑仑是一种新型苯二氮类镇静药物,通过作用于γ-氨基丁酸A型受体可产生同咪达唑仑类似的镇静催眠作用,其代谢通过血浆组织酯酶而不依赖肝肾,长时间输注无蓄积,对呼吸及循环功能影响轻微,在临床镇静诊疗应用中具有一定优势,已获批用于临床胃肠镜诊疗的镇静。有关其在临床镇静和全身麻醉方面有效性和安全性的试验正逐步开展,未来瑞马唑仑在临床中更为广泛的应用仍有待进一步探究。本文通过检索瑞马唑仑研究相关文献,就其作用机制、药动学、临床应用和安全性作一综述。
Remimazolam is a novel benzodiazepine. Like midazolam, it acts on γ-aminobutyric acid A receptors to induce sedation. Remimazolam is hydrolyzed by plasma tissue esterases rather than liver and renal metabolism. The concentration of remimazolam might not accumulate after long term infusion. The new sedative has a mild depression effects on respiratory and circulatory function, showing advantages in clinical sedation application. It is approved to provide procedural sedation for upper gastrointestinal endoscopy and colonoscopy. Several trials have been proceeding in terms of the safety and efficiency of remimazolam for clinical sedation and general anesthesia. Further studies are needed to explore more clinical application of remimazolam. The action mechanism, pharmacokinetics, clinical application and safety of remimazolam are introduced in this paper by searching references on remimazolam.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。